Join Us for a Free CME Lunch Satellite Symposium
Sunday, October 16, 2022
11:30 a.m. to 12 p.m. (CT): Registration and Lunch
12 to 1 p.m. (CT): Educational Program
Omni Nashville Hotel
Legends Ballroom D
250 Rep. John Lewis Way South, Nashville, TN 37203
The past two decades of research in severe asthma have changed our understanding of this complex, heterogeneous condition that includes a host of inflammatory subtypes and clinical manifestations with variations in endotype, phenotype and biomarkers/cytokines. Most patients with severe eosinophilic or allergic asthma treated with a biologic experience some degree of clinical improvement. Yet it is increasingly evident that many of these patients have unmet needs, including a need for more effective treatments to prevent asthma exacerbations. Newly approved and emerging therapies that target the epithelial alarmins represent an important opportunity to improve outcomes for patients with a broad range of asthma phenotypes.
This CME satellite symposium, presented by National Jewish Health, will unravel the complexity of severe asthma treatment by providing expert insights into the new paradigm of treatments, providing case examples, and offering a clinical reference aid to illuminate treatment options. Topics include the role of the epithelium in severe asthma, the downstream effect on alarmins, airway hyperresponsiveness, and matching phenotypes to therapeutic approaches for improved patient care.
Pulmonologists who treat patients with severe asthma.
||Ronald Balkissoon, MD
Division of Pulmonary, Critical Care and Sleep Medicine
Department of Medicine
National Jewish Health
||Flavia Cecilia Lega Hoyte, MD
Associate Professor of Medicine
Fellowship Training Program Director
Division of Allergy and Immunology
National Jewish Health and University of Colorado
||Monica Kraft, MD
Samuel Bronfman Department of Medicine
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, NY
Upon completion of this activity, participants should be able to:
- Describe the role of the airway epithelium in asthma.
- Define the epithelial alarmins and their impact on T2 and non-T2 airway inflammation, remodeling, and hyperresponsiveness in severe asthma.
- Evaluate the results of clinical trials of current and emerging therapies that target the epithelial alarmins in severe asthma.
- Match clinical characteristics and phenotypes to treatment targets.
For questions, please call the Office of Professional Education at National Jewish Health at 303.398.1000 or 800.844.2305, or email ProEd@njhealth.org.
Accreditation and Designation Statements:
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
National Jewish Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals.
If interested in attending, please RSVP below. Advanced registration is not required for this complimentary CME symposium, however, your RSVP helps us plan for the best experience possible. Please arrive early, as seating may be limited.
This symposium is not supported, endorsed, or accredited by the American College of Chest Physicians.